ID 406339859 · FY 2023–2024 · 2 years
ძირითად საქმიანობას წარმოადგენს მედიკამენტების და ბიოლოგიურად აქტიური დანამატების იმპორტი და საბითუმო რეალიზაცია.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Ratio | 2023 | 2024 |
|---|---|---|
| Margins | ||
| Gross Margin | 18.2% | 28.0% |
| EBITDA Margin | -6.8% | 0.9% |
| EBITDAR | -123 | 52 |
| EBITDAR Margin | -6.1% | 1.4% |
| EBIT Margin | -6.8% | 0.8% |
| Net Profit Margin | -7.6% | -0.4% |
| Operating Expense % of Sales | 25.0% | 27.1% |
| Returns | ||
| Return on Assets (ROA) | -5.2% | -0.4% |
| Return on Equity (ROE) | N/A | N/A |
| ROIC [EBIT / Invested Capital] | -4.8% | 0.9% |
| Leverage & liquidity | ||
| Debt-to-Assets | 104.8% | 104.8% |
| Debt-to-Equity | -19.84x | -20.44x |
| Debt-to-EBITDA | N/A | 107.19x |
| Equity-to-Assets | -5.3% | -5.1% |
| Net Debt | 3,031 | 3,362 |
| Cash & Equivalents | 13 | 37 |
| Total Debt | 3,044 | 3,399 |
| Efficiency & working capital | ||
| Inventory Turnover | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | N/A |
| Receivables Turnover | 2.09x | 2.87x |
| Days Sales Outstanding (DSO) | 175.0 | 127.3 |
| Payables Turnover | N/A | N/A |
| Days Payable Outstanding (DPO) | N/A | N/A |
| Cash Conversion Cycle | 175.0 days | 127.3 days |
| Asset Turnover | 0.69x | 1.11x |
| Cash flow & dividends | ||
| Operating Cash Flow | N/A | N/A |
| Free Cash Flow (OCF − Capex proxy) | N/A | N/A |
| Cash Conversion (OCF / EBITDA) | N/A | N/A |
| Dividends Declared | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in ₾ '000. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.